scholarly journals Ergospirometry and Echocardiography in Early Stage of Heart Failure with Preserved Ejection Fraction and in Healthy Individuals

Author(s):  
Eduardo Lima Garcia ◽  
Márcio Garcia Menezes ◽  
Charles de Moraes Stefani ◽  
Luiz Cláudio Danzmann ◽  
Marco Antonio Rodrigues Torres
2013 ◽  
Vol 19 (5) ◽  
pp. 405-418 ◽  
Author(s):  
Zh. D. Kobalava ◽  
Yu. V. Kotovskaya ◽  
S. V. Villevalde ◽  
R. E. Akhmetov ◽  
I. S. Goncharov ◽  
...  

The article discusses ventricular-vascular interaction that is a key factor of cardiovascular functioning and heart energy proile in healthy individuals, in aging, and in different pathological states.


2021 ◽  
Vol 20 (1) ◽  
pp. 2569
Author(s):  
Yu. A. Vasyuk ◽  
E. Yu. Shupenina ◽  
G. A. Namazova ◽  
T. I. Dubrovskaya

Heart failure with preserved ejection fraction (HFpEF) is a complex clinical syndrome associated with frequent hospitalizations, high mortality rates, and an absence of proven effective therapy. This type of heart failure is often accompanied by comorbidity that complicate the diagnosis of the underlying disease. The algorithm developed in 2016 does not take into account the heterogeneity of patients and course of HFpEF. Recently, new diagnostic algorithms (H2FPEF, HFA-PEFF) and biomarkers have appeared that allow detecting HFpEF at an early stage, taking into account the pathogenesis, which may contribute to development of new effective treatment methods.


2020 ◽  
Author(s):  
Aalexey Novoselov ◽  
Anastasia Kaburova ◽  
Maria Pokrovskaya ◽  
Boris Zaitchik ◽  
Stanislav Poyarkov ◽  
...  

Abstract Background Chronic heart failure (CHF) affects approximately 26 million people worldwide. Nearly half of CHF patients develop heart failure with preserved ejection fraction (HFpEF), which is associated with myocardial hypertrophy and fibrosis. Although chronic inflammation was suggested as a critical factor contributing to fibrosis development, a new hypothesis of CHF pathogenesis suggested that altered gut microbiota contributes to leaky gut phenotype development and promotes a systemic inflammatory state. CHF patients have an altered gut microbiome. However, the effect of gut microbiota on fibrosis development in HFpEF patients is not yet known. Thus, this clinical study involving HFpEF patients (n = 47) and healthy volunteers (n = 43) intended to identify the correlations between microbiota changes and fibrosis markers in HFpEF patients. Methods We used 16S rRNA metagenomic sequencing to identify the microbiota changes in HFpEF patients. Myocardial fibrosis was quantified using T1 myocardial mapping by using cardiac magnetic resonance. We also assessed the levels of microbial metabolites—trimethylamin N-oxide (TMAO) and short-chain fatty acids (SCFAs)—and measured bloodstream miRNAs and cytokines. The gut microbiome functions were simulated using PICRUSt algorithm. Results The gut microbial communities of HFpEF patients were markedly different from those of healthy individuals. The abundance of Faecalibacterium, Prevotella, and Pseudomonas was significantly decreased, whereas that of Lachnoclostridium, Blautia, Haemophilus, Dorea, Peptococcus, and Tyzzerella was increased in HFpEF patients. These changes could have affected TMAO metabolism and SCFA production: TMAO and hydroxypyruvate levels were significantly higher, whereas isovaleric, methylbutyric, and propionic acids were significantly lower in HFpEF patients than in healthy individuals. The simulation with PICRUSt revealed that genes responsible for starch fermentation, SCFA production, and secondary bile acid metabolism were downregulated. Correlation analysis identified the involvement of microbiota changes and miRNAs 183-3p and 193b-3p. Conclusions Gut microbiome composition shifts in HFpEF patients impair biochemical functions, increase TMAO production, and decrease SCFA biosynthesis. The significant decrease in Faecalibacterium could have the most prominent effect on the host physiology. However, this needs to be determined by conducting experiments on animal models, because the mechanism by which the microbiota is associated with cardiac fibrosis development is not yet known.


2019 ◽  
Vol 236 (3) ◽  
pp. 531-539 ◽  
Author(s):  
Christian Mühlfeld ◽  
Alexandra Rajces ◽  
Martin Manninger ◽  
Alessio Alogna ◽  
Marie‐Christin Wierich ◽  
...  

2008 ◽  
Vol 7 ◽  
pp. 62-63
Author(s):  
J NUNEZ ◽  
L MAINAR ◽  
G MINANA ◽  
R ROBLES ◽  
J SANCHIS ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document